ARTICLE | Company News
bioMerieux, ExonHit, Spectral Diagnostics deal
December 10, 2001 8:00 AM UTC
ExonHit and bioMerieux business bioMerieux-Pierre Fabre (Marcy l’Etoile, France) entered a 5-year deal to develop ExonHit’s Proof-Hit cancer diagnostic for breast and colon cancer. ExonHit will apply its differential analysis of transcripts with alternative splicing (DATAS) technology to bioMerieux’s clinical samples to define genetic signatures for use in Proof-Hit macroarrays. According to the companies, Proof-Hit analysis may indicate the presence and stage of cancer as well as treatment responses. ...